Show simple item record

dc.contributor.authorFu, Zhengen_US
dc.contributor.authorKitagawa, Yasuhideen_US
dc.contributor.authorShen, Ronglaien_US
dc.contributor.authorShah, Rajalen_US
dc.contributor.authorMehra, Rohiten_US
dc.contributor.authorRhodes, Danielen_US
dc.contributor.authorKeller, Peter J.en_US
dc.contributor.authorMizokami, Atsushien_US
dc.contributor.authorDunn, Rodney L.en_US
dc.contributor.authorChinnaiyan, Arul M.en_US
dc.contributor.authorYao, Zhien_US
dc.contributor.authorKeller, Evan T.en_US
dc.date.accessioned2007-03-19T17:26:19Z
dc.date.available2007-03-19T17:26:19Z
dc.date.issued2006-02-15en_US
dc.identifier.citationFu, Zheng; Kitagawa, Yasuhide; Shen, Ronglai; Shah, Rajal; Mehra, Rohit; Rhodes, Daniel; Keller, Peter J.; Mizokami, Atsushi; Dunn, Rodney; Chinnaiyan, Arul M.; Yao, Zhi; Keller, Evan T. (2006)."Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer." The Prostate 66(3): 248-256. <http://hdl.handle.net/2027.42/49524>en_US
dc.identifier.issn0270-4137en_US
dc.identifier.issn1097-0045en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/49524
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16175585&dopt=citationen_US
dc.description.abstractBACKGROUND Diminished expression of Raf kinase inhibitor protein (RKIP), an inhibitor of the Raf signaling cascade, promotes prostate cancer (PCa) metastasis in a murine model, suggesting that it is a metastasis suppressor gene. However, the prognostic significance of RKIP expression and its association with metastasis in PCa patients is unknown. METHODS To investigate RKIP protein expression is a prognostic marker in PCa we performed immunohistochemical staining for RKIP expression in tissue microarrays consisting of 758 non-neoplastic prostate tissues, primary tumors and metastases from 134 PCa patients. The Cox proportional-hazards model was used to adjust for covariates including Gleason score, tumor volume, tumor weight, clinical stage, digital rectal exam findings, serum PSA level and surgical margins. RESULTS RKIP expression was low in approximately 5%, 48%, and 89%of non-neoplastic prostate, primary tumors and metastases, respectively. Low RKIP expression in primary tumors was a strong positive predictive factor for PCa recurrence based on PSA levels. In patients whose primary tumors expressed high RKIP levels, the 7-year PSA recurrence rate was < 10%; whereas in patients with tumors with low RKIP expression the recurrence rate was 50% ( P  < 0.001). Multivariate analysis revealed RKIP was an independent prognostic factor ( P  < 0.001). CONCLUSION In contrast to increased expression of pro-tumorigenic genes, these results demonstrate decreased protein expression of a gene, for example, RKIP, can serve as a prognostic marker in PCa patients. © 2005 Wiley-Liss, Inc.en_US
dc.format.extent215122 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.subject.otherLife and Medical Sciencesen_US
dc.subject.otherCancer Research, Oncology and Pathologyen_US
dc.titleMetastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate canceren_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartments of Urology and Pathology, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartments of Urology and Pathology, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartments of Urology and Pathology, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartments of Urology and Pathology, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartments of Urology and Pathology, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartments of Urology and Pathology, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartments of Urology and Pathology, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartments of Urology and Pathology, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartments of Urology and Pathology, University of Michigan, Ann Arbor, Michigan ; Room 5304, CCGC building, 500 E. Medical Center Dr., University of Michigan, Ann Arbor, MI 48109-0940.en_US
dc.contributor.affiliationotherDepartment of Urology, Kanazawa University, Kanazawa City, Japanen_US
dc.contributor.affiliationotherDepartment of Urology, Kanazawa University, Kanazawa City, Japanen_US
dc.contributor.affiliationotherDepartment of Immunology, Tianjin Medical University, Tianjin, Chinaen_US
dc.identifier.pmid16175585en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/49524/1/20319_ftp.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1002/pros.20319en_US
dc.identifier.sourceThe Prostateen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record